EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical and molecular variations in Burkitt lymphoma

Eoghan O'Connor, Patricia Scanlan, Owen Patrick Smith, Melinda Halasz

Translational Oncology · 2026-01 · 63 · 102611

DOI: 10.1016/j.tranon.2025.102611 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-01. Verfasst von Eoghan O'Connor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Systems Biology Ireland, UCD School of Medicine, University College Dublin, Ireland. Electronic address: Eoghan.oconnor@ucd.ie. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taighde Éireann - Research Ireland, Children’s Health Foundation, Pathological Society of Great Britain and Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

• EBV-positive and EBV-negative Burkitt lymphoma are discrete biologic groups based on molecular features regardless of epidemiologic context and geographic location. • The presence of apoptotic gene mutations in Burkitt lymphoma can differ significantly based on EBV status. • EBV-negative Burkitt lymphoma is more dependent on ID3/TCF3/CCND3 axis deregulation compared to EBV-positive Burkitt lymphoma. • EBV-negative Burkitt lymphoma relies on oncogenic mutations in the ARF-MDM2-TP53 apoptotic pathway, while EBV-positive Burkitt lymphoma gains anti-apoptotic activity as a direct effect of EBV on apoptotic pathways. • Co-infection of chronic malaria with early EBV infection leads to aberrant AID expression. Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma, historically classified into three subtypes; endemic, sporadic and immunodeficiency associated BL. Accumulating evidence suggests that Epstein-Barr virus (EBV)-positive and EBV-negative BL represent biologically distinct entities. In this review, we aim to compare the clinicopathological and molecular differences in BL in the context of EBV status and chronic malaria infection. From our review, clinical features of BL vary by both EBV status and geographical region, reflecting underlying epidemiological differences. The cell of origin may also differ between EBV-positive and EBV-negative cases. At a molecular level, differences based on EBV status include variations in the immunoglobulin ( IG ):: MYC translocation breakpoints, mutations in the inhibitor of DNA binding 3 ( ID3 )/ transcription factor 3 ( TCF3 )/ cyclin D3 ( CCND3 ) signalling axis, the anti-apoptotic effects of EBV latency gene products, differences in the alternative reading frame (ARF)/ mouse double minute 2 (MDM2)/p53 and ataxia-telangiectasia mutated (ATM)/ ATM and RAD3-related (ATR) pathways, and deregulation of B-cell leukemia/lymphoma 2 (BCL-2) family proteins. We further discuss the theory that aberrant activation-induced cytidine deaminase (AID) expression, in the setting of EBV infection and chronic malaria exposure, is the most likely aetiology of endemic BL. This review provides a comprehensive summary of key molecular differences between EBV-positive and EBV-negative BL, that may guide the development of future targeted therapeutic strategies. Created in BioRender. Halasz, M. (2025) https://BioRender.com/g9ln8jq .

Schlagwörter

Stichwörter der Autor:innen

BurkittEBVLymphomaMYCMalaria

Autor:innen und Institutionen

  • Systems Biology Ireland, UCD School of Medicine, University College Dublin, Ireland. Electronic address: Eoghan.oconnor@ucd.ie.
  • Muhimbili National Hospital and Tumaini la Maisha Children's Cancer Charity, Dar es Salaam, Tanzania.
  • National Children's Cancer Service, Children's Health Ireland at Crumlin, Ireland; School of Medicine, Faculty of Health Sciences, Trinity College Dublin, Ireland.
  • Systems Biology Ireland, UCD School of Medicine, University College Dublin, Ireland. Electronic address: Melinda.halasz@ucd.ie.

Förderung

  • Taighde Éireann - Research Ireland
  • Children’s Health Foundation
  • Pathological Society of Great Britain and Ireland

Zitieren

APA

O'Connor, E., Scanlan, P., Smith, O. P., & Halasz, M. (2026). Clinical and molecular variations in Burkitt lymphoma. Translational Oncology, 63, 102611. https://doi.org/10.1016/j.tranon.2025.102611

Vancouver

O'Connor E, Scanlan P, Smith OP, Halasz M. Clinical and molecular variations in Burkitt lymphoma. Translational Oncology. 2026;63:102611. doi:10.1016/j.tranon.2025.102611

BibTeX
@article{OConnor2026,
  author = {O'Connor, Eoghan and Scanlan, Patricia and Smith, Owen Patrick and Halasz, Melinda},
  title = {Clinical and molecular variations in Burkitt lymphoma},
  journal = {Translational Oncology},
  year = {2026},
  volume = {63},
  pages = {102611},
  doi = {10.1016/j.tranon.2025.102611}
}
Kostenlos starten →